Search

Your search keyword '"Uriona, Sonia"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Uriona, Sonia" Remove constraint Author: "Uriona, Sonia" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
23 results on '"Uriona, Sonia"'

Search Results

1. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

2. Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018

3. Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine

4. Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente

5. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

6. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

7. Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units

8. Características de los pacientes con enfermedad neumocócica invasora que requieren ingreso en la unidad de cuidados intensivos

9. Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain

10. Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection

11. Enfermedad neumocócica invasiva en niños menores de 60 meses, antes y después de la introducción de la vacuna conjugada 13-valente

12. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

13. Characteristics of patients with invasive pneumococcal disease requiring admission to intensive care units

14. Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study

15. Epidemiological, Clinical, and Microbiological Characteristics of Serotype-3 Streptoccocus pneumoniae Infection after a Partial Introduction of the 13-Valent Pneumococcal Conjugate Vaccine: A Prospective Observational Study

16. Pneumococcal serotypes in children and relationship with clinical presentation and antimicrobial susceptibility in the PCV13 era

17. Necrotizing pneumonia due to Streptococcus pneumoniaein children during the period of non-systematic use of PCV13 in Catalonia, Spain

18. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

19. A case of respiratory toxigenic diphtheria: contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015

21. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

22. A molecular epidemiological study of human parainfluenza virus type 3 at a tertiary university hospital during 2013–2015 in Catalonia, Spain

23. Vaccine Failures in Patients Properly Vaccinated with 13-Valent Pneumococcal Conjugate Vaccine in Catalonia, a Region with Low Vaccination Coverage

Catalog

Books, media, physical & digital resources